Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Background: Two thirds (62%) of metastatic breast cancer (MBC) patients in Western Europe have human epidermal growth factor receptor 2 (HER2)-negative disease, for which anthracyclines and taxanes are recommended as first-line treatments, followed by microtubule-targeting agents such as capecitabin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Majethia, Unnati, Kontoudis, Ilias, De Rosendo, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471375/
https://www.ncbi.nlm.nih.gov/pubmed/37663315
http://dx.doi.org/10.36469/9834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471375/
https://www.ncbi.nlm.nih.gov/pubmed/37663315
http://dx.doi.org/10.36469/9834

Ejemplares similares